Published in J Neurol on March 06, 2009
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol (2015) 1.05
Clinical correlates of grey matter pathology in multiple sclerosis. BMC Neurol (2012) 0.94
Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. Nat Rev Neurol (2015) 0.87
Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. Neurol Sci (2015) 0.83
Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine. J Neurol (2011) 0.82
Advances in multiple sclerosis research in 2009. J Neurol (2010) 0.80
Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis. J Neurol (2011) 0.77
Accurate, robust, and automated longitudinal and cross-sectional brain change analysis. Neuroimage (2002) 8.03
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn Reson Med (1989) 4.68
Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain (1999) 4.41
Multimodal image coregistration and partitioning--a unified framework. Neuroimage (1997) 4.26
Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol (2001) 4.06
Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol (2004) 3.23
Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol (1999) 2.61
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain (2000) 2.28
Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler (2003) 2.24
Thalamic neurodegeneration in multiple sclerosis. Ann Neurol (2002) 2.20
The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry (1962) 2.18
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Nuclear magnetic resonance imaging of the brain in multiple sclerosis. Lancet (1981) 1.84
Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann Neurol (2000) 1.60
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol (2003) 1.55
Quantitative magnetization transfer mapping of bound protons in multiple sclerosis. Magn Reson Med (2003) 1.49
A magnetization transfer imaging study of normal-appearing white matter in multiple sclerosis. Neurology (1995) 1.38
Correlation of magnetization transfer ratio with clinical disability in multiple sclerosis. Ann Neurol (1994) 1.35
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol (1978) 1.17
In vivo assessment of the brain and cervical cord pathology of patients with primary progressive multiple sclerosis. Brain (2001) 1.17
The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage (2005) 1.16
Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain (2006) 1.16
An interleaved sequence for accurate and reproducible clinical measurement of magnetization transfer ratio. Magn Reson Imaging (1996) 1.11
Magnetisation transfer ratio and mean diffusivity of normal appearing white and grey matter from patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (2001) 1.07
Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities. Mult Scler (2003) 0.99
A magnetization transfer histogram study of normal-appearing brain tissue in MS. Neurology (2000) 0.99
Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis. Mult Scler (2008) 0.97
Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler (2007) 0.97
Optimizing the association between disability and biological markers in MS. Neurology (2001) 0.96
Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 0.95
The relationship between lesion and normal appearing brain tissue abnormalities in early relapsing remitting multiple sclerosis. J Neurol (2002) 0.93
The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study. J Neurol (2003) 0.93
Abnormalities in normal appearing tissues in early primary progressive multiple sclerosis and their relation to disability: a tissue specific magnetisation transfer study. J Neurol Neurosurg Psychiatry (2006) 0.92
Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. J Neurol Sci (2001) 0.92
Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry (2006) 0.91
European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. Arch Neurol (2004) 0.90
Increasing normal-appearing grey and white matter magnetisation transfer ratio abnormality in early relapsing-remitting multiple sclerosis. J Neurol (2005) 0.87
The effect of interferon beta-1b on quantities derived from MT MRI in secondary progressive MS. Neurology (2003) 0.86
Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. J Neurol (2002) 0.86
Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage (2003) 0.83
Analysis of MTR histograms in multiple sclerosis using principal components and multiple discriminant analysis. Magn Reson Med (2001) 0.82
Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 12.74
Identification of FAP locus genes from chromosome 5q21. Science (1991) 11.41
Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science (1991) 6.15
Hydroxyproline arabinosides in the plant kingdom. Plant Physiol (1971) 4.67
Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain (1997) 3.87
Exploring the relationship between alcohol consumption and non-fatal or fatal stroke: a systematic review. Addiction (2001) 3.59
Sequence and expression of mRNAs encoding the alpha 1 and alpha 2 subunits of a DHP-sensitive calcium channel. Science (1988) 3.38
Genetic heterogeneity and mitochondrial DNA heteroplasmy in Leber's hereditary optic neuropathy. J Med Genet (1989) 3.25
The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain (1987) 3.15
Central nervous system sarcoidosis--diagnosis and management. QJM (1999) 3.11
Detection of FeLV antigen by indirect immunofluorescence in ELISA/CITE negative cats. Vet Rec (1995) 3.05
A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat Genet (1996) 3.00
The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain (2000) 2.84
Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain (2008) 2.67
Comparison of high-fat and high-protein diets with a high-carbohydrate diet in insulin-resistant obese women. Diabetologia (2004) 2.66
Structure and functional expression of alpha 1, alpha 2, and beta subunits of a novel human neuronal calcium channel subtype. Neuron (1992) 2.65
Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol (1984) 2.64
Occurrence of a multiple sclerosis-like illness in women who have a Leber's hereditary optic neuropathy mitochondrial DNA mutation. Brain (1992) 2.62
Molecular determinants of dysplasia in colorectal lesions. Cancer Res (1994) 2.62
The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity (1994) 2.59
Failure of 3,4-diaminopyridine to reverse conduction block in inflammatory demyelinating neuropathies. Ann Neurol (1993) 2.56
Diffusion tensor imaging of lesions and normal-appearing white matter in multiple sclerosis. Neurology (1999) 2.54
Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain (1996) 2.54
Electrocardiographic detection of left ventricular hypertrophy: development and prospective validation of improved criteria. J Am Coll Cardiol (1985) 2.50
Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology (2000) 2.47
Diffusion tensor imaging can detect and quantify corticospinal tract degeneration after stroke. J Neurol Neurosurg Psychiatry (2000) 2.44
Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell (1992) 2.38
The persistent vegetative state. BMJ (1995) 2.35
Regional brain blood flow in man during acute changes in arterial blood gases. J Physiol (2012) 2.34
Management of acute optic neuritis. Lancet (2002) 2.33
Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity (1998) 2.31
Illiteracy among Medicaid recipients and its relationship to health care costs. J Health Care Poor Underserved (1994) 2.30
Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nat Genet (1999) 2.28
Granulocyte colony-stimulating factor as a marker for bacterial infection in neonates. J Pediatr (1996) 2.27
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
Azole resistance in Candida albicans. J Med Vet Mycol (1986) 2.17
Beta1-subunit of the Ca2+-activated K+ channel regulates contractile activity of mouse urinary bladder smooth muscle. J Physiol (2001) 2.15
Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol (1999) 2.14
Hydroxyproline heterooligosaccharides in Chlamydomonas. Science (1972) 2.12
Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology (2008) 2.11
Desmoplastic malignant melanoma. J Am Acad Dermatol (1995) 2.08
Association between wild type and mutant APC gene products. Cancer Res (1993) 2.08
Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol (1989) 2.08
Pathogenesis of Guillain-Barré syndrome. J Neuroimmunol (1999) 2.08
The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res (2001) 2.06
Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry (1996) 2.02
Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain (2002) 2.01
Tropical spastic paraparesis and human T cell lymphotropic virus type 1 in the United Kingdom. Brain (1989) 2.00
Acute disseminated encephalomyelitis. MRI findings and the distinction from multiple sclerosis. Brain (1990) 2.00
The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain (1998) 1.99
The chemical composition of the cell wall of Chlamydomonas gymnogama and the concept of a plant cell wall protein. J Cell Biol (1974) 1.95
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
Incidence of common compressive neuropathies in primary care. J Neurol Neurosurg Psychiatry (2006) 1.90
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology (1993) 1.87
Proton magnetic resonance spectroscopy of an acute and chronic lesion in multiple sclerosis. Lancet (1991) 1.86
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology (1999) 1.82
Neuropathological abnormalities of the corpus callosum in schizophrenia: a diffusion tensor imaging study. J Neurol Neurosurg Psychiatry (2000) 1.81
Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology (2008) 1.80
Primary progressive multiple sclerosis. Brain (1997) 1.80
Precise estimate of fundamental in-vivo MT parameters in human brain in clinically feasible times. Magn Reson Imaging (2002) 1.80
Expression of the APC tumor suppressor protein in oligodendroglia. Glia (1996) 1.77
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Inactivation of both APC alleles in human and mouse tumors. Cancer Res (1994) 1.75
Regulatory mechanisms controlling expression of the DAN/TIR mannoprotein genes during anaerobic remodeling of the cell wall in Saccharomyces cerevisiae. Genetics (2001) 1.74
Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry (1991) 1.70
A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry (2006) 1.70
Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain (1996) 1.69
Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood (1993) 1.69
Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain (1994) 1.68
The clinical effectiveness and cost-effectiveness of screening programmes for amblyopia and strabismus in children up to the age of 4-5 years: a systematic review and economic evaluation. Health Technol Assess (2008) 1.67
Transverse-momentum and pseudorapidity distributions of charged hadrons in pp collisions at square root of s = 7 TeV. Phys Rev Lett (2010) 1.67
Utility of transcranial Doppler ultrasound for the integrative assessment of cerebrovascular function. J Neurosci Methods (2011) 1.67
Lipid composition of Saccharomyces cerevisiae as influenced by growth temperature. Biochim Biophys Acta (1972) 1.66
Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol (2000) 1.66
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology (1998) 1.62
Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology (1997) 1.60
Determining the cost of genital warts: a study from Ireland. Sex Transm Infect (2008) 1.60
Search for supersymmetry using final states with one lepton, jets, and missing transverse momentum with the ATLAS detector in √s=7 TeV pp collisions. Phys Rev Lett (2011) 1.60
Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology (1994) 1.60
Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry (2005) 1.59
Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology (2002) 1.59
High field MRI correlates of myelin content and axonal density in multiple sclerosis--a post-mortem study of the spinal cord. J Neurol (2003) 1.59
Investigation of MS normal-appearing brain using diffusion tensor MRI with clinical correlations. Neurology (2001) 1.58
Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology (1998) 1.58
Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology (1999) 1.58
Fatigue is not associated with raised inflammatory markers in multiple sclerosis. Neurology (2001) 1.58
The British Isles survey of multiple sclerosis in twins. Neurology (1994) 1.57
Study of the mass and spin-parity of the Higgs boson candidate via its decays to Z boson pairs. Phys Rev Lett (2013) 1.56
Spinal cord repair in MS: does mitochondrial metabolism play a role? Neurology (2010) 1.56
Spatial mapping of T2 and gadolinium-enhancing T1 lesion volumes in multiple sclerosis: evidence for distinct mechanisms of lesion genesis? Brain (1999) 1.56
Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain (2007) 1.55
The role of beta-hydroxyaspartate and adjacent carboxylate residues in the first EGF domain of human factor IX. EMBO J (1988) 1.54